Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...

From electronic health records and blood tests to the stream of data from wearable devices, the amount of health information people generate is accelerating rapidly. Yet, many users struggle to ...

Credit: Image generated by VentureBeat with FLUX-pro-1.1-ultra A quiet revolution is reshaping enterprise data engineering. Python developers are building production data pipelines in minutes using ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Official support for free-threaded Python, and free-threaded improvements Python’s free-threaded build promises true parallelism for threads in Python programs by removing the Global Interpreter Lock ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

They look, move and even smell like the kind of furry Everglades marsh rabbit a Burmese python would love to eat. But these bunnies are robots meant to lure the giant invasive snakes out of their ...

The new ‘COPILOT’ function uses AI to generate summaries, tags, tables, and more based on a group of cells. The new ‘COPILOT’ function uses AI to generate summaries, tags, tables, and more based on a ...